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Keywords Lysosomes, dextran sulphate, sulphatase, albumin fragmentation, protein kinase C. tact and fragmented albumin is reversed in both experimental diabetes [5, 6] and in subjects with Type I (insulin-dependent) diabetes mellitus [7] . Aminoguanidine and ramipril have been shown to normalise the fragmentation process in streptozotocin (STZ)-diabetic rats [6] . The exact anatomical location of this ªdegradation pathwayº has not been found but it is most likely to occur by endocytosis and lysosomal degradation in proximal tubule cells. Histochemical and electron microscopical studies [8] have shown that, following endocytosis, larger molecular weight proteins are degraded within the lysosomes of the epithelial cells in proximal convoluted tubules.
125 I-labelled bovine serum albumin has also been shown to be degraded by lysates of rat kidney lysosomes [9] . The degradation pathway seems to be non-specific since all proteins tested to date have been shown to be degraded, including horseradish peroxidase, immunoglobulin G and albumin [1±7], the extent of degradation varying from protein to protein. The pathway will affect the concentration of protein excretion measured as existing immunochemical assays do not detect fragments but only intact material [2, 5, 7] .
Alterations in lysosomal enzyme activity, which have been reported to be reduced in short-term (up to three weeks) diabetic rats, could affect the degradation pathway. For example, renal proteolytic activity was reduced by about 25 % in isolated glomeruli [10] and proximal tubules [11] , and lower activities (~20±25 %) of lysosomal enzymes such as cathepsins L, B and D [12, 13] have been reported. We have also shown that the decreased cathepsin activity continues after 24 weeks of diabetes [6] . Although lysosomal enzyme activity has been measured in ex situ or in vitro preparations, no direct estimation of lysosomal activity in vivo has been made.
Recently, a direct method of estimating lysosomal processing in vivo has been developed, which estimates lysosomal sulphatase activity by measuring the degree of desulphation of tritium labelled dextran sulphate ([ 3 H]DSO 4 ) during renal passage [14, 15] . Sulphatase, a specific lysosomal hydrolase, has been shown to have considerable biochemical activity in glomerular cells of the rat [16, 17] 4 molecule in the urine collected from control rats [15] . The decrease in desulphation is likely to be a direct consequence of the decrease in sulphatase activity in vivo which has been shown to be linked with vesicles that are transported to lysosomes [18] . Dextran sulphate (radius range 20±50) glomerular capillary wall (GCW) permeability will not be significantly altered in STZ-diabetic rats as its glomerular sieving is identical to dextran at sufficiently high concentration and dextran (radius range 20±50) fractional clearance is not altered in diabetic nephropathy [19±21] . Therefore, the reduction in sulphatase activity is likely to reflect a decreased activity of enzymes or altered intracellular processing associated with lysosomal degradation in diabetes [6, 10±13] . For example, the activity of cathepsin and metalloprotease in glomeruli has been shown to decrease after only 4 days of diabetes and to continue to decrease 5 weeks after the onset of diabetes in insulin untreated rats [22] . The decreased lysosomal enzyme activity observed in the STZ-diabetic rat is consistent with the decrease in albumin fragmentation observed as early as 4 weeks after the onset of diabetes [5] . Therefore, the desulphation of [ 3 H]DSO 4 could be used as a direct in vivo marker of lysosomal enzyme activity. Because sulphatase is specifically located in lysosomes, other proteolytic events which are not lysosomal do not contribute to the changes observed in diabetes.
In this study we determined the in vivo degree of desulphation of [ 
Materials and methods
STZ-diabetic rat model. Fasting male Sprague Dawley rats (Animal Resource Centre, Perth, Australia, Heidelberg, Australia), aged between 6 and 7 weeks and weighing between 200 and 250 g, were chosen at random to receive an intravenous injection of STZ (Sigma Chemical, St. Louis, Mont., USA) at a dose of 50 mg/kg or sodium citrate buffer (pH 4.5 for control rats only). Only diabetic animals with blood glucose of greater than 15 mmol/l were included in the study. Diabetic animals were given either 4U of long-acting insulin (Ultralente, Novo Nordisk, Bagsvaerd, Denmark) three times a week (for the 1, 2, 3 and 4 week time points) or 2U of long-acting insulin daily (for the 12 week time point) to maintain body weight and to prevent ketoacidosis. All animals had free access to rat food and water.
For the 12 week study, diabetic and control animals were randomised to receive one of the following three drug regimens: (1) no treatment, (2) aminoguanidine (Fluka Chemica, Buchs, Switzerland) at a dose of 1 g/l for diabetic rats and 3 g/l for control rats in drinking water; (3) ramipril (Hoechst, Frankfurt, Germany) at a dose in drinking water of 3 mg/l for diabetic rats and 9 mg/l for control rats for 12 weeks. These doses were chosen because they ameliorate albuminuria [23±25] .
The following parameters were measured every 4 weeks throughout the study: body weight, blood glucose by glucometer (Accutrend, Boehringer Mannheim GmbH Biochemica, Mannheim, Germany), systolic blood pressure (BP) measured by tail-cuff plethysmography in conscious, warmed rats [26] , glycohaemoglobin (GHb) by high-performance liquid chroma-tography (CLC330 GHb Analyzer, Primus, Kansas City, Mont., USA) [27] and glomerular filtration rate (GFR) by a single-injection isotopic technique using 99 m Tc-DTPA developed in our laboratory [28] . In addition, urine was collected from animals placed in individual metabolic cages for 24 h to measure the albumin excretion rate (AER) by an in-house RIA as described previously [29] . The interassay coefficient of variation was 7 % at a concentration of 180 ng/ml and the detection limit of the assay was 31.2 ng/ml.
Tritium labelling of dextran sulphate. DSO 4 was labelled with tritium (molecular weight, 48 000) according to a method described previously [30] . This involved a brief exposure to sodium boro-[ 3 H]hydride (Du Pont, Wilmington, Detroit, USA) followed by extensive dialysis for 3 days against distilled water and then for a further 2 days against phosphate buffered saline (PBS; 136.9 mmol/l NaCl, 2.68 mmol/l KCl, 8.1 mmol/l Na 2 H-PO 4 , 1.5 mmol/l KH 2 PO 4 , pH 7.4). The dialysed preparation was applied to a PD-10 column immediately before being used to remove any free tritium. The specific activity of the sample was determined to be 9.48´10 6 dpm/mg by measuring the hexose content [31] .
Processing of dextran sulphate in vivo. Control and diabetic rats at 1, 2, 3, 4 and 12 weeks after the onset of diabetes, were intravenously injected with 2.0 mg [ 3 H]DSO 4 which corresponds to 1.91´10 7 dpm, in the tail vein and maintained in a metabolic cage for 3 h with free access to food and water. The urine collected during this period was analysed by ion-exchange using a Q-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) column. The samples were buffered with 6 mol/l Urea, 0.05 mol/l Tris, 0.05 % (w/v) CHAPS, at pH 7.0, and eluted with a linear gradient of 0.15±2.5 mol/l NaCl, in the same buffer at 30 ml/h collecting a total of 80 fractions of 3 ml. Fraction densities were measured in a PAAR DMA55 densitometer (Graz, Austria) at 21 C. Column recoveries were between 95±105 %.
Counting of radioactivity. Radioactivity of tritium labelled material was measured by scintillation counting in a Wallac 1409 liquid scintillation analyser (Wallac, Finland), using a 1 : 4 aqueous sample to Optiphase scintillant ratio.
Statistics. Data are expressed as mean standard error where n represents the number of determinations. The albumin excretion rate is expressed as geometric mean´/¸tolerance factor. Normally, distributed variables in different groups were compared by analysing of variance, using the Statview program (Brain Power, Calabasas, Calif., USA). Comparisons between group means were carried out by Fisher's least significant difference method. A p value of less than 0.05 was considered statistically significant.
Results
Characterisation of the STZ-diabetic rat model. Only the data for the 12 week study are shown (Table 1) but similar results were obtained for the control rats and STZ-diabetic rats 1, 2, 3 and 4 weeks after the onset of diabetes. Rats had noticeably higher glucose and GHb concentration after 12 weeks of diabetes when compared with control rats. Aminoguanidine or ramipril therapy did not influence glycaemic control in diabetic rats. Control rats treated with aminoguanidine or ramipril had similar glucose and GHb levels to untreated control rats (Table 1) . Systolic BP was significantly reduced in diabetic rats receiving ramipril (Table 1) . Systolic BP was not affected by aminoguanidine treatment. Body weight was significantly lower in diabetic than in control rats (Table 1) . At the conclusion of the study, the kidney weight-tobody weight ratio was increased in diabetic rats compared with control rats (Table 1) . Aminoguanidine or ramipril therapy did not influence the kidney weight-to-body weight ratio in diabetic rats. Diabetes was associated with an increase in GFR when compared with control rats and was also only normalised by treatment with ramipril and not aminoguanidine. Control rats treated with aminoguanidine or ramipril had similar GFRs to untreated control rats (Table 1) . Urine volumes as measured over a 24 h period were much higher in diabetic rats compared with control rats. Treatment with aminoguanidine or ramipril did not influence urine volume. Control rats treated with aminoguanidine or ramipril had similar urine volumes to untreated control rats (Table 1) .
Diabetes was associated with a significantly increased AER, as measured by RIA over the 12 week study period, when compared with control rats (Table 1). Treatment of diabetic rats with ramipril but not aminoguanidine prevented an increase in AER. Albuminuria was similar in untreated control rats and in those receiving aminoguanidine or ramipril.
Sulphatase activity in control and STZ-diabetic rat urine. Figure 1 shows a representative elution profile of 4 (as calculated from the area under the curve), and thus sulphatase activity in urine from control and diabetic rats 1, 2, 3 and 4 weeks after the onset of diabetes was found to be 65.6 0.8 % desulphated (n = 4) in urine collected from control rats, 63.4 1.4 % desulphated (n = 4) in urine collected from 1 week diabetic rats, 57.4 1.4 % desulphated (n = 4, p < 0.005 vs control) in urine collected from 2 week diabetic rats, 56.8 1.3 % desulphated (n = 4, p < 0.005 vs control) in urine collected from 3 week diabetic rats and 52.9 2.2 % desulphated (n = 4, p < 0.005 vs control) in urine collected from 4 week diabetic rats. Note that no desulphation was detected in plasma due to extrarenal sources which could have contributed to the desulphation observed in the urine during the 3 h period of urine collection.
The degree of desulphation of [ 3 H]DSO 4 in the urine collected from 12 week control and STZ-diabetic rats with and without aminoguanidine or ramipril treatment is shown in Table 2 . Diabetes was associated with a considerable decrease in the amount of desulphated [ 
Discussion
Previous studies have demonstrated that [ 3 H]DSO 4 undergoes desulphation during transglomerular transport [14, 15] . This study showed that in the percentage of totally desulphated [ 3 H]DSO 4 in urine collected from STZ-diabetic rats decreases as early as two weeks after the onset of diabetes when compared with control rats. These results are in accordance with previous findings of a significant decrease in sulphatase activity in glomerular extracts obtained from 4 week STZ-diabetic rats [15] . This desulphation process occurs within the lysosomes since sulphatase, which is the enzyme responsible for the desulphation, is an acid hydrolase that is specific for lysosomes. Although the changes in desulphation could correspond to a decrease in lysosomal sulphatase activity, they could also reflect changes in the kinetics of the intracellular trafficking of the [ The reduction in sulphatase activity is likely to reflect alterations synonymous with decreased activities of other enzymes associated with lysosomal degradation in diabetes [6, 10±13] . For example, decreased cathepsin and metalloprotease activities in glomeruli have been shown to decrease after only 4 days of diabetes and to continue to decrease 5 weeks after the onset of diabetes in insulin untreated rats [10] . Transforming growth factor beta, which is upregulated in diabetic nephropathy, has been shown to decrease lysosomal cathepsin activity and consequently protein degradation under hyperglycaemic conditions [32] . The decreased lysosomal enzyme activity observed in the STZ-diabetic rat is consistent with the decrease in albumin fragmentation associated with the ªdegrada-tion pathwayª observed as early as 4 weeks after the onset of diabetes [5] . Thus, the decrease in lysosomal activity in diabetes is probably one of the initial events in the evolution of the disease together with the increased permeability of albumin [33] . This study shows that both aminoguanidine and ramipril prevent the diabetes-induced changes in lysosomal processing as measured by the desulphation of [ (Table 1) . Aminoguanidine did not affect systolic BP and AER while ramipril prevented increases in both systolic BP and AER (Table 1) . Further, urine volume did not decrease in diabetic rats treated with either drug when compared with control rats.
The different effects of aminoguanidine on sulphatase activity as compared with albuminuria are probably related to the different time ramipril and aminoguanidine take to respond and prevent albuminuria. A number of studies have shown that aminoguanidine is effective over the long term but that its efficacy could vary over time. We have previously shown that aminoguanidine prevents albuminuria in STZdiabetic rats at 32 weeks but not at 8 and 16 weeks [24] whereas in another study [6] we showed that aminoguanidine was effective at 8 weeks. Studies with ramipiril have shown that it is consistently effective in preventing albuminuria [6, 25] . The apparent discrepancy between changes in sulphatase activity and albuminuria (reflecting proteolytic lysosomal processing) is due to the measurement of the intracellular processing of two totally different substrates by different lysosomal enzymes in different renal cells [6, 14] . Rampiril and aminoguanidine could well have different time-dependent effects at any of the distinct processing points within the cell.
The way in which aminoguanidine and ramipril inhibit the diabetes-induced changes in lysosomal processing suggests that they act on a shared intrarenal pathway when compared with their modes of action at a systemic level. Therefore aminoguanidine and ramipril could either affect the activity of the lysosomal enzymes or the intracellular trafficking of molecules to and from lysosomes. Long-term ACE inhibition in a model of chronic renal failure has been shown to restore normal lysosomal cathepsin activity in the heart [34] . However, we have shown that ramipril does not restore cathepsin activity in lysosomes isolated from STZ-diabetic rats 24 weeks after the onset of diabetes [6] . Both of these studies, however, were done in vitro which could affect the measurement of enzyme activity.
We have also recently shown that both aminoguanidine and ramipril inhibit the diabetes-induced activation of protein kinase C (PKC) in glomeruli. In addition, advanced glycation end product-receptor interactions have been shown to include PKC activation in cultured cells [35] while angiotensin II binding to AT 1 receptors in proximal tubular cells has been shown to lead to G-protein coupled activation of phospholipase C and D which in turn increases diacylglycerol (DAG) production and PKC activity [36] . The shared intrarenal pathway is likely to involve PKC through its direct actions on the intracellular trafficking of molecules to and from the lysosomes. For example, the effect of PKC on vesicular trafficking has been shown to be a regulatory mechanism that controls endo-and exocytosis of proteins [37±40] including albumin [41] . Farshori and Holzbaur have shown an increased frequency of vesicular transport along microtubules following activation of PKC and subsequent phosphorylation of dynactin in neurones [42] . In cultured mesangial cells, a glucoseactivated PKC-dependent disruption of the cytoskeleton has been observed [43] .
We observed in this study that the diabetes-induced changes in renal lysosomal processing could be one of the initial events in the development of diabetic nephropathy. Aminoguanidine and ramipril, which are known for their different mechanism of action, seem to have similar effects in preventing diabetes-induced changes in lysosomal processing either by a direct effect on enzyme activity within the lysosome or by an effect on the trafficking of molecules to and from the lysosome which could be controlled by PKC.
